Cyclooxygenase 2 inhibitor: Difference between revisions
imported>Robert Badgett mNo edit summary |
mNo edit summary |
||
| (7 intermediate revisions by 3 users not shown) | |||
| Line 1: | Line 1: | ||
Cyclooxygenase 2 inhibitors are defined as "a subclass of [[cyclooxygenase]] | {{subpages}} | ||
'''Cyclooxygenase 2 inhibitors''' are defined as "a subclass of [[cyclooxygenase inhibitor]]s with specificity for [[cyclooxygenase 2|cyclooxygenase-2]]".<ref>{{cite web |url=http://www.nlm.nih.gov/cgi/mesh/2007/MB_cgi?term=Cyclooxygenase+2+Inhibitors |title=Cyclooxygenase 2 Inhibitors|author=National Library of Medicine |accessdate=2007-11-18 |format= |work=}}</ref> | |||
==Pharmacology== | |||
The benefit of selectivity for the cyclooxygenase-2 enzyme is that analgesia occurs while gastrointestinal complications due to inhibition of prostaglandin synthesis by cyclooxygenase-1 in the gastrointestinal mucosa are reduced.<ref name="pmid-16968830">{{cite journal |author=Graham DJ |title=COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense |journal=JAMA |volume=296 |issue=13 |pages=1653–6 |year=2006 |pmid=16968830 |doi=10.1001/jama.296.13.jed60058}}</ref> | |||
Selective COX-2 inhibition may suppress antiplatelet and vasodilatory effects from endothelial cell synthesis of prostacyclin.<ref name="pmid-16968830"/> This leaves vasoconstriction, platelet aggregation, and thrombosis from platelet thromboxane A2 mediated by COX-1 intact.<ref name="pmid-16968830"/> | |||
==Medical uses== | ==Medical uses== | ||
[[Rofecoxib]] was voluntarily withdrawn from the market by Merck & Co in September, 2004 due to increased cardiovascular complications.<ref>{{cite web |url=http://www.fda.gov/bbs/topics/news/2004/NEW01122.html |title=FDA Issues Public Health Advisory on Vioxx as its Manufacturer Voluntarily Recalls the Product |accessdate=2007-11-18 |format= |work=|year=2004}}</ref> | |||
== | [[Celecoxib]] remains marketed and according to the [[Food and Drug Administration]] is indicated for the treatment of acute pain, various types of arthritis, dysmenorrhea, and "to reduce the number of adenomatous colorectal polyps in familial adenomatous polyposis".<ref name="">{{cite web |url=http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3624#nlm34067-9 |title=Celebrex (Celecoxib) capsule |accessdate=2007-11-18 |format= |work=|year=2007}}</ref> | ||
==References== | ==References== | ||
<references/> | <references/>[[Category:Suggestion Bot Tag]] | ||
[[Category: | |||
Latest revision as of 17:01, 3 August 2024
Cyclooxygenase 2 inhibitors are defined as "a subclass of cyclooxygenase inhibitors with specificity for cyclooxygenase-2".[1]
Pharmacology
The benefit of selectivity for the cyclooxygenase-2 enzyme is that analgesia occurs while gastrointestinal complications due to inhibition of prostaglandin synthesis by cyclooxygenase-1 in the gastrointestinal mucosa are reduced.[2]
Selective COX-2 inhibition may suppress antiplatelet and vasodilatory effects from endothelial cell synthesis of prostacyclin.[2] This leaves vasoconstriction, platelet aggregation, and thrombosis from platelet thromboxane A2 mediated by COX-1 intact.[2]
Medical uses
Rofecoxib was voluntarily withdrawn from the market by Merck & Co in September, 2004 due to increased cardiovascular complications.[3]
Celecoxib remains marketed and according to the Food and Drug Administration is indicated for the treatment of acute pain, various types of arthritis, dysmenorrhea, and "to reduce the number of adenomatous colorectal polyps in familial adenomatous polyposis".[4]
References
- ↑ National Library of Medicine. Cyclooxygenase 2 Inhibitors. Retrieved on 2007-11-18.
- ↑ 2.0 2.1 2.2 Graham DJ (2006). "COX-2 inhibitors, other NSAIDs, and cardiovascular risk: the seduction of common sense". JAMA 296 (13): 1653–6. DOI:10.1001/jama.296.13.jed60058. PMID 16968830. Research Blogging.
- ↑ FDA Issues Public Health Advisory on Vioxx as its Manufacturer Voluntarily Recalls the Product (2004). Retrieved on 2007-11-18.
- ↑ Celebrex (Celecoxib) capsule (2007). Retrieved on 2007-11-18.